# Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine

> **NCT00635128** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 415 (actual)

## Conditions studied

- Poliomyelitis
- Diphtheria
- Tetanus
- Acellular Pertussis

## Interventions

- **BIOLOGICAL:** Boostrix-Polio

## Key facts

- **NCT ID:** NCT00635128
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-01
- **Primary completion:** 2008-07-08
- **Final completion:** 2008-07-08
- **Target enrollment:** 415 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635128, "Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00635128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*